Jeffrey A. Sosman, MD, from the Vanderbilt-Ingram Cancer Center, discusses a trial comparing two doses of ipilimumab for patients with metastatic melanoma.
Jeffrey A. Sosman, MD, Professor of Medicine, Director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses a trial comparing two dosages of ipilimumab for patients with metastatic melanoma.
The trial, which compared 3 mg/kg and 10 mg/kg of ipilimumab, was completed quickly because of the high rate of patient accrual in Europe, Sosman says. At the time of the trial, ipilimumab had been approved in the U.S. but not in Europe.
Sosman expects the results from this trial to reveal a sense of the toxicity difference between two doses of ipilimumab.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More